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Prediagnostic presentations of Parkinson’s disease in 
primary care: a case-control study
Anette Schrag, Laura Horsfall, Kate Walters, Alastair Noyce, Irene Petersen
Summary
Background Parkinson’s disease has an insidious onset and is diagnosed when typical motor features occur. Several 
motor and non-motor features can occur before diagnosis, early in the disease process. We aimed to assess the association 
between ﬁ rst presentation of several prediagnostic features in primary care and a subsequent diagnosis of Parkinson’s 
disease, and to chart the timeline of these ﬁ rst presentations before diagnosis.
Methods We identiﬁ ed individuals with a ﬁ rst diagnosis of Parkinson’s disease and those without Parkinson’s disease 
from Jan 1, 1996, to Dec 31, 2012, from The Health Improvement Network UK primary care database. Codes were 
extracted for a range of possible prediagnostic or early symptoms, comprising motor features (tremor, rigidity, balance 
impairments, neck pain or stiﬀ ness, and shoulder pain or stiﬀ ness), autonomic features (constipation, hypotension, 
erectile dysfunction, urinary dysfunction, and dizziness), neuropsychiatric disturbances (memory problems, late-onset 
anxiety or depression, cognitive decline, and apathy), and additional features (fatigue, insomnia, anosmia, hypersalivation 
and rapid-eye-movement sleep behaviour disorder) in the years before diagnosis. We report the incidence of symptoms 
recorded in more than 1% of cases per 1000 person-years and incidence risk ratios (RRs) for individuals with and without 
Parkinson’s disease at 2, 5, and 10 years before diagnosis.
Findings 8166 individuals with and 46 755 individuals without Parkinson’s disease were included in the study. 
Apathy, REM sleep behaviour disorder, anosmia, hypersalivation, and cognitive decline were all reported in less 
than 1% of people per 1000 person-years and were excluded from further analyses. At 2 years before Parkinson’s 
disease diagnosis, the incidence of all studied prediagnostic features except neck pain or stiﬀ ness was higher in 
patients who went on to develop Parkinson’s disease (n=7232) than in controls (n=40 541). At 5 years before 
diagnosis, compared with controls (n=25 544), patients who went on to develop Parkinson’s disease (n=4769) had a 
higher incidence of tremor (RR 13·70, 95% CI 7·82–24·31), balance impairments (2·19, 1·09–4·16), constipation 
(2·24, 2·04–2·46), hypotension (3·23, 1·85–5·52), erectile dysfunction (1·30, 1·11–1·51), urinary dysfunction 
(1·96, 1·34–2·80), dizziness (1·99, 1·67–2·37), fatigue (1·56, 1·27–1·91), depression (1·76, 1·41–2·17), and anxiety 
(1·41, 1·09–1·79). At 10 years before diagnosis of Parkinson’s disease, the incidence of tremor (RR 7·59, 95% CI 
1·11–44·83) and constipation (2·01, 1·62–2·49) was higher in those who went on to develop Parkinson’s disease 
(n=1680) than in controls (n=8305).
Interpretation A range of prediagnostic features can be detected several years before diagnosis of Parkinson’s disease in 
primary care. These data can be incorporated into ongoing eﬀ orts to identify individuals at the earliest stages of the 
disease for inclusion in future trials and to help understand progression in the earliest phase of Parkinson’s disease.
Funding Parkinson’s UK.
Copyright © Schrag et al. Open Access article distributed under the terms of CC BY.
Introduction
Parkinson’s disease is the second most common 
neurodegenerative disease worldwide and incidence is 
rising with changing population demographics.1 Present 
treatment strategies are aimed at improving symptoms, 
but increasing eﬀ orts are being made to trial 
neuroprotective drugs that potentially slow or prevent the 
development of symptoms.2 These drugs are most likely 
to be beneﬁ cial when used early in the disease process, 
before substantial neuronal loss has occurred.2,3 
Diagnosis of Parkinson’s disease relies on the 
identiﬁ cation of the classical motor symptoms, which are 
incorporated into clinical diagnostic criteria.4 However, at 
least 50% of the nigrostriatal neurons have already been 
lost at the time of diagnosis and pathological 
abnormalities are thought to start in other brain regions 
earlier than nigrostriatal degeneration.5 Compared with 
people who do not develop Parkinson’s disease, several 
non-motor symptoms occur more frequently in patients 
with Parkinson’s disease before the onset of typical motor 
symptoms, including depression, constipation, anosmia, 
and fatigue.6 When in the disease course each of these 
symptoms ﬁ rst occurs and whether they could be 
detected in primary care is unknown.7 Insight into the 
ﬁ rst clinical presentations of these prediagnostic features 
would help to delineate the pathophysiology of early 
Parkinson’s disease progression and to identify people at 
increased risk of development of overt Parkinson’s 
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disease, who would be eligible for inclusion in clinical 
trials of neuroprotective strategies. 
We used a large primary care database in the UK with 
prospectively recorded data on presentations, diagnoses, 
and prescriptions to assess the association between 
several prediagnostic features and a subsequent 
diagnosis of Parkinson’s disease, and to chart the 
timeline of these presentations before diagnosis.
Methods
Study design and data sources
After a comprehensive meta-analysis on possible 
prediagnostic features of Parkinson’s disease,8 we 
undertook a study in The Health Improvement Network 
(THIN) to compare prediagnostic features that were 
recorded in primary care in individuals who developed 
Parkinson’s disease with those in matched controls. 
THIN holds anonymised longitudinal medical records 
for over 11 million individuals registered with more than 
500 general practices in the UK, representing around 6% 
of the population.9 These data are collected from general 
practices that have elected to join the THIN quality data 
recording scheme using the Vision practice management 
software (In Practice Systems, London, UK). THIN is a 
large and comprehensive source of patient data from 
consultation records. Information on symptoms, 
diagnoses, interventions, and referrals to secondary care 
are electronically recorded as Read codes, a hierarchical 
coding system used in UK primary care.10,11 Information 
recorded in the system includes data on all drug 
prescriptions and records of health indicators such as 
height, weight, blood pressure, smoking status, and 
laboratory test results recorded by general practitioners 
(GPs), and information on levels of social deprivation 
(Townsend score) as quintile scores from 1 (least deprived) 
to 5 (most deprived). THIN data are representative of the 
UK general practice population in terms of demographics 
and frequency and type of consultations requested by 
patients, and electronically coded diagnoses have been 
shown to be accurate when compared with the gold 
standard (GP questionnaire, primary care medical record, 
or hospital correspondence).12,13 Data on smoking levels in 
THIN are similar to those reported in The Health Survey 
for England.14 
Only pseudonymous patient data are collected in 
THIN. No patient names, addresses, dates of birth, or 
National Health Service (NHS) numbers are available; 
therefore, explicit patient consent is not necessary. 
Patients are informed of the use of their data via posters 
and general practice leaﬂ ets, and they have the option to 
opt out of the data collection. The THIN data collection 
scheme has been approved by an NHS multicentre 
research ethics committee and has been reviewed several 
times since data collection started. Additionally, strict 
governance rules exist concerning the use of THIN, and 
stringent legal and technical restrictions are in place to 
protect patient conﬁ dentiality. The University College 
London Scientiﬁ c Review Committee approved the 
present study.
Study population 
We identiﬁ ed all individuals in THIN who had a Read 
code diagnosis of Parkinson’s disease and at least two 
anti-parkinsonian drug prescriptions. A similar method 
for identiﬁ cation of people with Parkinson’s disease has 
been validated in another large primary care database in 
the UK.15 Diagnostic Read codes for Parkinson’s disease 
were identiﬁ ed using published methods (appendix).16 
The earliest date of Read code diagnosis or anti-
parkinsonian drug prescription was taken as the index 
date. Individuals with diagnoses before age 50 years were 
excluded, as were those with secondary parkinsonism, 
dementia before Parkinson’s disease diagnosis, drug-
induced parkinsonism, or schizophrenia, because these 
individuals are likely to have had substantial exposure to 
dopamine antagonist drugs.
We used stratiﬁ ed sampling within each GP practice to 
extract a control population without a diagnosis of 
Parkinson’s disease but similar characteristics in terms 
of age, sex, and registration period. Within each GP 
practice, we divided patients with Parkinson’s disease 
into categories according to sex, 5-year age band, and 
year of index date (ie, diagnosis). Up to six controls per 
Parkinson’s disease patient were selected in the same 
sex, age band, and registration period categories by a 
random sampling routine in Stata. For individuals 
without Parkinson’s disease, age and registration period 
were deﬁ ned using the date of a GP consultation selected 
using the random sampling routine in Stata (index date).
We included data recorded from Jan 1, 1995, or when 
practices were consistently contributing good levels of 
data, deﬁ ned as using acceptable mortality recording17 
and acceptable computer usage in terms of the 
numbers of consultations, health measurements, and 
prescriptions.18 Individuals were included only if they 
had at least 1 year of such data before the index date. This 
inclusion criterion also ensured that individuals had at 
least 1 year between registration with the GP practice and 
diagnosis of Parkinson’s disease, which limits the 
possibility of inclusion of patients with Parkinson’s 
disease that was diagnosed previously but ﬁ rst recorded 
by the new GP during the patient registration period.19 
Thus, patients with Parkinson’s disease included in the 
analyses were those diagnosed between Jan 1, 1996 (after 
exclusion of individuals with less than 1 year of follow-up 
from Jan 1, 1995) and Dec 31, 2012 (the most recent full 
year of data available at the time of analysis). 
Data extraction
We examined symptoms previously reported to be 
associated with subsequent diagnosis of Parkinson’s 
disease on the basis of published work, which are also 
likely to be recorded in the patients’ electronic health 
record. On the basis of a recently undertaken systematic 
For THIN see http://www.thin-
uk.com
See Online for appendix
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literature review8 and a further Medline search for 
the terms “pre-diagnostic” OR “prediagnostic” OR 
“prodromal” and “Parkinson’s disease” from March, 2011, 
to April, 2014, symptoms initially included in the analysis 
were late-onset (>50 years of age) anxiety and depression, 
fatigue, apathy, insomnia, rapid eye movement (REM) 
sleep behaviour disorder, balance impairments, dizziness, 
hypotension, anosmia, hyper salivation, constipation, 
urinary dysfunction, erectile dysfunction, memory 
problems, neck pain or stiﬀ ness, shoulder pain or 
stiﬀ ness, rigidity, tremor, and cognitive decline. All 
symptoms were deﬁ ned using Read code lists (appendix).16 
Additionally, we used prescriptions for anxiolytics, 
antidepressants, drugs for constipation, hypnotics, and 
drugs for erectile dysfunction to identify symptoms of 
anxiety, depression, constipation, insomnia, and erectile 
dysfunction, respectively. A symptom presentation was 
identiﬁ ed if either the Read code or prescription of a 
symptom-speciﬁ c drug was recorded. Any symptoms or 
diagnoses coded shortly after registration with the GP 
potentially represent prevalent health issues and not new 
diagnoses (ie, prevalent cases). Therefore, using a 
previously described method,19 we plotted the monthly 
incidence of each prediagnostic symptom within 2 years 
after GP registration and the point at which the incidence 
became roughly constant was selected to deﬁ ne a period 
within which diagnoses were excluded. By this method, 
the exclusion period was 1 year after GP registration for 
anxiety or depression and 6 months for all other 
symptoms (data not shown).
Statistical analysis
We calculated the incidence and 95% CIs of prediagnostic 
symptom presentations per 1000 person-years for each 
year within 10 years before the index date for individuals 
with and without Parkinson’s disease. We excluded 
symptoms with a recorded prevalence of less than 1% in 
patients with Parkinson’s disease in THIN from further 
analysis. We calculated the risk ratios (RRs) and 95% CIs 
for prediagnostic symptom presentations at 2, 5, and 
10 years before index dates (Parkinson’s disease diagnosis 
or a date selected using the random sampling routine in 
Stata for those without a diagnosis of Parkinson’s disease).
For the periods from 0–2 years, 2–5 years, and 
5–10 years before to the index date, we present the overall 
occurrence of prediagnostic symptoms as absolute 
numbers and percentages. 
Role of the funding source
The funder of the study had no role in study design, data 
collection, data analysis, data interpretation, or writing of 
the report. All authors had full access to all the data in the 
study and the corresponding author had ﬁ nal 
responsibility for the decision to submit for publication.
Results
8166 individuals with any follow-up data and 46 755 
without Parkinson’s disease were included in the study. 
At 2 years, 7232 patients were included in the Parkinson’s 
disease group and 40 541 in the control group; at 5 years 
these numbers were 4769 and 25 544, and at 10 years they 
Total With ≥2 years of retrospective data With ≥5 years of retrospective data With ≥10 years of retrospective data
Parkinson’s 
disease (n=8166)
Controls 
(n=46 755)
Parkinson’s 
disease (n=7232)
Controls 
(n=40 541)
Parkinson’s 
disease (n=4769)
Controls 
(n=25 544)
Parkinson’s 
disease (n=1680)
Controls
(n=8305)
Sex
Men 4859 (60%) 27 684 (59%) 4323 (60%) 24 076 (59%) 2885 (60%) 15 330 (60%) 1024 (61%) 5017 (60%)
Women 3307 (40%) 19 071 (41%) 2909 (40%) 16 465 (41%) 1884 (40%) 10 214 (40%) 656 (39%) 3288 (40%)
Age at index date 75 (68–81) 74 (68–80) 75 (68–80) 74 (68–80) 75 (68–81) 75 (68–80) 75 (68–80) 75 (68–80)
Person-years of data available 
before index date
5 (3–5) 5 (3–5) 5 (4–5) 5 (4–5) 9 (7–11) 9 (7–11) 12 (11–14) 12 (11–14)
Smoking status
Never 4396 (54%) 20 589 (44%) 3892 (54%) 17 938 (44%) 2609 (55%) 11 386 (45%) 913 (54%) 3723 (45%)
Past 2076 (25%) 12 196 (26%) 1880 (26%) 10 763 (27%) 1376 (29%) 7556 (30%) 590 (35%) 2892 (35%)
Present 711 (9%) 7594 (16%) 622 (9%) 6556 (16%) 393 (8%) 4059 (16%) 122 (7%) 1202 (15%)
Data missing 983 (12%) 6376 (14%) 838 (12%) 5284 (13%) 391 (8%) 2543 (10%) 55 (3%) 488 (6%)
Social deprivation (Townsend 
score)
1 (least deprived) 2397 (29%) 12 572 (27%) 2178 (30%) 11 091 (27%) 1524 (32%) 7344 (29%) 559 (33%) 2557 (31%)
2 1948 (24%) 11 086 (24%) 1718 (24%) 9675 (24%) 1147 (24%) 6165 (24%) 405 (24%) 2031 (24%)
3 1572 (19%) 9318 (20%) 1385 (19%) 8069 (20%) 857 (18%) 5015 (20%) 304 (18%) 1628 (20%)
4 1268 (16%) 7862 (17%) 1108 (15%) 6731 (17%) 716 (15%) 4096 (16%) 242 (14%) 1242 (15%)
5 (most deprived) 756 (9%) 4800 (10%) 654 (9%) 4079 (10%) 415 (9%) 2439 (10%) 145 (9%) 733 (9%)
Data missing 225 (3%) 1117 (2%) 189 (3%) 896 (2%) 110 (2%) 485 (2%) 25 (1%) 114 (1%)
Data are number (%) or median (IQR).
Table 1: Characteristics of patients with Parkinson’s disease and controls 
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were 1680 and 8305. The characteristics between the two 
groups were similar with the exception of smoking 
status, for which the number of present smokers in the 
Parkinson’s disease group was about half that in the 
control group, and social deprivation was lower in the 
Parkinson’s disease group than in controls (table 1).
Prevalence of REM sleep behaviour disorder, apathy, 
cognitive decline, anosmia, and excessive saliva were less 
than 1% and were therefore excluded from further 
analyses. The most common prediagnostic symptom of 
Parkinson’s disease within 2 years before diagnosis was 
tremor, with 41% of individuals reporting symptoms to 
their GP compared with less than 1% of controls (table 2).
Most presentations of tremor occurred within 2 years 
before the Parkinson’s disease diagnosis (RR 32·54, 
95% CI 24·94–42·90), although incidence of tremor was 
already higher in the Parkinson’s disease compared with 
the control group at 5 years (13·70, 7·82–24·31) and 
10 years (7·59, 1·11–44·83) before diagnosis (ﬁ gure 1; 
table 3). For the other motor features, the group of 
individuals later diagnosed with Parkinson’s disease had 
a higher incidence of balance impairments at 2 years and 
5 years before diagnosis, shoulder pain or stiﬀ ness at 
2 years, and rigidity at 2 years compared with controls 
(ﬁ gure 1; table 3). Incidence of neck pain or stiﬀ ness did 
not diﬀ er between the groups (table 3).
Within the 2 years before Parkinson’s disease diagnosis, 
the most common neuropsychiatric presentation was 
depression, which occurred in 10% of individuals with 
later diagnosis of Parkinson’s disease and 4% of controls 
(table 2). Incidence of depression with onset over the age 
of 50 years was higher in patients with Parkinson’s 
disease than in those without at 2 years (RR 2·15, 95% CI 
1·85–2·49) and at 5 years (1·76, 1·41–2·17), but not at 
10 years (2·00, 0·19–12·21) before diagnosis of 
Parkinson’s disease (ﬁ gure 2; table 3). For the other 
neuropsychiatric features, compared with controls the 
individuals later diagnosed with Parkinson’s disease had 
a higher incidence of prediagnostic anxiety with onset 
over the age of 50 years at 2 years and at 5 years and 
memory problems at 2 years (ﬁ gure 2; table 3).
Within 0 to <2 years ≥2 years to <5 years ≥5 years to <10 years
Parkinson’s disease 
(n=7232)
Controls 
(n=40 541)
Parkinson’s disease 
(n=4769)
Controls 
(n=25 544)
Parkinson’s disease 
(n=1680)
Controls 
(n=8305)
Tremor 2946 (41%) 184 (<1%) 311 (7%) 118 (<1%) 29 (2%) 41 (<1%)
Constipation 2326 (32%) 7598 (19%) 1196 (25%) 3890 (15%) 335 (20%) 1202 (14%)
Fatigue 761 (11%) 2129 (5%) 430 (9%) 1472 (6%) 180 (11%) 618 (7%)
Dizziness 725 (10%) 2411 (6%) 486 (10%) 1629 (6%) 206 (12%) 723 (9%)
Depression 696 (10%) 1724 (4%) 312 (7%) 1035 (4%) 94 (6%) 409 (5%)
Shoulder pain or stiﬀ ness 528 (7%) 2263 (6%) 407 (9%) 1729 (7%) 175 (10%) 803 (10%)
Anxiety 624 (9%) 1505 (4%) 333 (7%) 1039 (4%) 136 (8%) 504 (6%)
Neck pain or stiﬀ ness 301 (4%) 1613 (4%) 224 (5%) 1301 (5%) 128 (8%) 667 (8%)
Urinary dysfunction 338 (5%) 815 (2%) 167 (4%) 459 (2%) 53 (3%) 170 (2%)
Erectile dysfunction 293/4323 (7%) 1434/24 076 (6%) 242/2885 (8%) 1072/15 330 (7%) 116/1024 (11%) 416/5017 (8%)
Insomnia 314 (4%) 1286 (3%) 190 (4%) 850 (3%) 85 (5%) 386 (5%)
Balance impairments 300 (4%) 379 (1%) 78 (2%) 196 (1%) 21 (1%) 62 (1%)
Hypotension 153 (2%) 346 (1%) 80 (2%) 204 (1%) 27 (2%) 61 (1%)
Memory problems 197 (3%) 520 (1%) 61 (1%) 187 (1%) 8 (<1%) 47 (1%)
Rigidity 201 (3%) 52 (<1%) 11 (<1%) 36 (<1%) 3 (<1%) 16 (<1%)
Data are number of patients (%). Symptoms listed according to frequency in the 0–2 year column. Only individuals who had follow-up for the complete time period were 
included (ie, at least 2, 5, and 10 years, respectively).
Table 2: Number of patients with symptoms before diagnosis or index date
Figure 1: Incidence of motor symptoms of Parkinson’s disease
Bars are 95% CIs, based on the sample size of each group. Neck pain and stiﬀ ness symptoms are not shown 
because the diﬀ erence between groups was not signiﬁ cant at any year.
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Constipation was the most common autonomic 
complaint within the 2 years before Parkinson’s disease 
diagnosis, with 32% of patients in the Parkinson’s 
disease group aﬀ ected versus 19% of controls (table 2). 
Incidence of constipation was higher in those with 
Parkinson’s disease than in those without at 10 years 
(RR 2·01, 95% CI 1·62–2·49), 5 years (2·24, 2·04–2·46), 
and 2 years before diagnosis (2·44, 2·29–2·59; ﬁ gure 3; 
table 2). Dizziness was ﬁ rst reported in 10% of patients 
with Parkinson’s disease and 6% of controls within 
5 years of diagnosis and at 2 years, and hypotension was 
noted in 2% compared with 1% of patients at 5 years and 
at 2 years (ﬁ gure 3; table 3). Erectile dysfunction was 
more common in those who went on to develop 
Parkinson’s disease compared with controls at 5 years 
and 2 years before diagnosis, and urinary dysfunction 
occurred more frequently at 5 years and 2 years before 
diagnosis (ﬁ gure 3; table 3). 
Individuals later diagnosed with Parkinson’s disease 
also had a higher incidence than controls of insomnia 
(RR 1·38, 95% CI 1·11–1·70; ﬁ gure 2; table 3) and of 
fatigue (1·79, 1·55–2·06) at 2 years before diagnosis, and 
of fatigue at 5 years before diagnosis (1·56, 1·27–1·91; 
ﬁ gure 3; table 3).
Discussion
In this study, we show that individuals with a subsequent 
diagnosis of Parkinson’s disease present to their primary 
care physicians with several motor and non-motor 
features of Parkinson’s disease that might represent 
prediagnostic features. At 2 years before Parkinson’s 
disease diagnosis, except neck pain or stiﬀ ness, the 
incidence of all examined features with prevalence of 1% 
or more was higher in patients who went on to develop 
Parkinson’s disease than in controls. At 5 years before 
diagnosis, compared with controls, patients with 
Parkinson’s disease had a higher incidence of tremor, 
balance impairments, constipation, hypotension, erectile 
dysfunction, urinary dysfunction, dizziness, fatigue, 
depression, and anxiety. At 10 years before diagnosis of 
Parkinson’s disease, the incidence of tremor and 
constipation was already higher in those who went on to 
develop Parkinson’s disease than in controls.
Some non-motor symptoms have previously been 
shown to occur frequently before diagnosis of Parkinson’s 
disease compared with controls,8 but several of the 
symptoms investigated in this Article, such as fatigue, 
dizziness, hypotension, and memory problems, have not 
been reported quantitatively before. Many of the 
previously identiﬁ ed prediagnostic features of Parkinson’s 
disease are non-speciﬁ c, such as anosmia or constipation, 
whereas others are speciﬁ c but rare, such as REM sleep 
behaviour disorder. Several ongoing or recently completed 
studies20–22 aim to address more than one of these features, 
together with other markers such as genetic risk factors 
or investigations such as transcranial sonography or ¹²³I-
2β-carbomethoxy-3β-(4-iodophenyl)-N-(3-ﬂ uoropropyl)-
nortropane (¹²³I-β-CIT SPECT), to harness their 
combined potential to identify the earliest stages of 
Parkinson’s disease and deﬁ ne at-risk populations.23 
However, to the best of our knowledge, only one study24 
has addressed a combination of postulated premotor 
symptoms together in a primary care population (panel). 
That nested case-control study, which was based on a 
smaller database of about 12 000 patients, addressed a 
range of features in the period within 2 years before 
Parkinson’s disease diagnosis, and found that patients 
At 2 years At 5 years At 10 years
Tremor 32·54 (24·94–42·90) 13·70 (7·82–24·31) 7·59 (1·11–44·83)
Constipation 2·44 (2·29–2·59) 2·24 (2·04–2·46) 2·01 (1·62–2·49)
Fatigue 1·79 (1·55–2·06) 1·56 (1·27–1·91) 1·52 (0·96–2·32)
Dizziness 1·80 (1·58–2·05) 1·99 (1·67–2·37) 1·30 (0·85–1·92)
Depression 2·15 (1·85–2·49) 1·76 (1·41–2·17) 2·00 (0·19–12·21)
Shoulder pain or stiﬀ ness 1·35 (1·17–1·56) 1·11 (0·91–1·35) 1·24 (0·85–1·79)
Anxiety 1·89 (1·58–2·25) 1·41 (1·09–1·79) 1·39 (0·86–2·16)
Neck pain or stiﬀ ness 1·01 (0·83–1·23) 1·18 (0·94–1·47) 0·98 (0·65–1·42)
Urinary dysfunction 2·27 (1·80–2·85) 1·96 (1·34–2·80) 1·92 (0·84–4·06)
Erectile dysfunction 1·30 (1·06–1·57) 1·30 (1·11–1·51) 1·00 (0·56–1·69)
Insomnia 1·38 (1·11–1·70) 1·18 (0·86–1·58) 1·46 (0·82–2·48)
Balance impairments 2·43 (1·69–3·44) 2·19 (1·09–4·16) 0·67 (0·02–5·00)
Hypotension 3·03 (2·18–4·18) 3·23 (1·85–5·52) 1·37 (0·25–5·08)
Memory problems 2·13 (1·44–3·11) 0·87 (0·26–2·24) 3·46 (0·29–30·20)
Rigidity 2·63 (1·11–5·79) 1·39 (0·25–5·15) ··*
Symptoms listed according to frequency in the at 2 years column. Data are incidence risk ratios (95% CI) for patients 
with Parkinson’s disease compared with controls. *Cannot be calculated because an insuﬃ  cient number of 
presentations was recorded.
Table 3: Incidence risk ratios of symptom presentations recorded in over 1% of patients at 2, 5, and 
10 years before diagnosis
Figure 2: Incidence of neuropsychiatric symptoms and insomnia
Bars are 95% CIs, based on the sample size of each group.
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with Parkinson’s disease more often presented with 
functional somatic symptoms, constipation, hyper-
hidrosis, and sleep disorders than did controls. In another 
study,25 93 patients with Parkinson’s disease who were 
retrospectively asked about prediagnositic symptoms 
reported a mean of 7·6 symptoms before diagnosis.
The present study is, to our knowledge, the largest 
and most comprehensive of its kind, in which a large 
number of prediagnostic features were investigated in 
the same cohort. Additionally, to our knowledge, this 
study is the ﬁ rst to chart the ﬁ rst occurrence of these 
early symptom presentations over time before diagnosis 
of Parkinson’s disease. The results of this study support 
the existence of a long prediagnostic phase of 
Parkinson’s disease, which comprises both motor and 
non-motor features.6,26,27 These features include some of 
the typical symptoms of Parkinson’s disease, such as 
tremor, rigidity, or balance impairments, which can be 
too non-speciﬁ c, atypical or diﬃ  cult to interpret in 
isolation to be used for diagnosis of Parkinson’s disease 
at initial presentation. Also, even if symptoms are 
typical there can be a delay between their ﬁ rst 
presentation and diagnosis of Parkinson’s disease. The 
high incidence of tremor, even 10 years before diagnosis 
of Parkinson’s disease, might be due to some patients 
already having clinical features of mild but typical 
Parkinson’s disease before formal diagnosis. In 
addition, an association between essential tremor and 
Parkinson’s disease has been suggested,28 which 
suggests that some patients might have had essential 
tremor before developing Parkinson’s disease or that 
they had a long duration of isolated tremor as a feature 
of their Parkinson’s disease.  However, the data in this 
analysis do not allow diﬀ erentiation of these syndromes.
The features that we identiﬁ ed as occurring many years 
before diagnosis included those that are often regarded 
as symptoms of advanced Parkinson’s disease (eg, 
hypotension, balance impairments, and urinary 
dysfunction), that are non-speciﬁ c (eg, fatigue, insomnia, 
and constipation), or that they are likely to be initially 
diagnosed as diﬀ erent disorders (eg, depression and 
anxiety, memory problems, or shoulder pain). 
Nevertheless, all of these symptoms are not only common 
in typical Parkinson’s disease,29 but also might represent 
the earliest stages of Parkinson’s disease.
We noted a temporal pattern of diﬀ erent prediagnostic 
features that supports the present hypothesis of 
pathophysiological progression of Parkinson’s disease,5,30 
ﬁ rst involving autonomic, limbic, and somatomotor 
systems, followed by the midbrain and substantia nigra. 
The similar incidence of neck pain or stiﬀ ness in 
individuals with subsequent Parkinson’s disease and 
controls might be either because neck pain is a less 
speciﬁ c symptom or because it is not a prediagnostic 
feature of Parkinson’s disease.
The incidence of presentation of autonomic 
dysfunction in primary care was increased in people 
who went on to develop Parkinson’s disease compared 
with controls. In particular, constipation was more 
common in patients than in controls already 10 years 
before diagnosis. Constipation is thought to be an early 
feature of Parkinson’s disease,31–34 and peripheral 
Parkinson’s disease pathology, including α-synuclein 
neuropathology in the enteric nervous system, might 
precede the classic changes in midbrain and limbic 
areas.7 Other autonomic features with which individuals 
presented to their primary care physicians were 
dizziness, urinary dysfunction, hypotension, and 
erectile dysfunction (in men), which are rarely reported 
prediagnostic features of Parkinson’s disease.7,31,35 
Erectile dysfunction has been associated with a 
diagnosis of Parkinson’s disease more than 10 years 
later.36 In our study, its incidence was higher in patients 
than in controls already 5 years before diagnosis of 
Parkinson’s disease. However, its incidence seemed to 
be similar to that in controls at the time of Parkinson’s 
disease diagnosis, possibly because erectile dysfunction 
is under-reported in the Parkinson’s disease group at 
the time of diagnosis of Parkinson’s disease or patients 
did not complain about this symptom in the face of 
other, more troublesome symptoms.
Figure 3: Incidence of autonomic symptoms and fatigue
Bars are 95% CIs, based on the sample size of each group.
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Neuropsychiatric presentations, such as depression 
and anxiety with ﬁ rst onset over the age of 50 years and 
memory problems, were also more common in patients 
than controls in the years before diagnosis of Parkinson’s 
disease, supporting the early occurrence of these non-
motor complications.7 Memory problems were more 
frequently reported by patients than controls 2 years 
before diagnosis, and this ﬁ nding might be an 
underestimate because cognitive impairment might be 
under-reported or under-recognised and because 
dementia was an exclusion criterion for this study.
Recognition of this prediagnostic phase of Parkinson’s 
disease is helpful in understanding its pathophysiological 
progression and for the development of strategies to 
identify individuals at risk in the general population. Our 
ﬁ nding of multiple prediagnostic symptoms, and their 
pattern of presentation in the 10 years before diagnosis, 
suggests that screening might be feasible in the general 
population; screening for these symptoms is possible 
with established instruments,37 but would need to be 
carefully considered and several preconditions, such as 
beneﬁ t of early treatment, should be fulﬁ lled for such a 
future screening programme.38
Furthermore, this study provides clinical support for the 
early involvement of extrastriatal structures in the 
development of Parkinson’s disease, as suggested by 
ﬁ ndings from pathological and imaging studies in 
Parkinson’s disease and incidental Lewy body disease.35 
Parkinson’s disease has been suggested to begin in 
extranigral structures, including the olfactory bulb or lower 
brainstem nuclei, or even sympathetic nervous system 
structures such as the gastric myenteric plexus.5 Early non-
motor symptoms, such as autonomic dysfunction, and 
memory problems and psychiatric impairment, including 
symptoms often thought to be non-speciﬁ c, such as fatigue 
and insomnia, occurred more frequently in individuals 
with later diagnosis of Parkinson’s disease than in controls 
in this study, and might be a result of this early brainstem 
or extranigral pathological change.
The main limitation of this study is that data were not 
collected through active enquiry about prediagnostic 
features of Parkinson’s disease, but were derived from 
already collected longitudinal primary care data. Thus, 
we cannot be certain about the diagnostic accuracy of the 
symptom presentations. Some overestimation might 
have occurred—eg, for balance impairments, which are 
usually thought of as a feature of advanced Parkinson’s 
disease rather than early Parkinson’s disease. The 
incidence of some factors was probably underestimated, 
especially for those that are not particularly troublesome 
or are under-recognised, such as anosmia, hyper-
salivation, apathy, or REM sleep behaviour disorder. This 
underestimation might explain the low incidence of 
these speciﬁ c symptoms in primary care data and might 
have led to underestimation of other symptoms. 
Nevertheless, the sample size in this study was large; 
therefore, the data are probably a good representation of 
presentation of Parkinson’s disease in primary care in 
the UK. Additionally, the data were collected prospectively 
without a recall or selection bias towards diagnosis of 
Parkinson’s disease and therefore are a true-life 
representation of presentations to primary care. The 
results therefore provide information on the type of data 
that could be used in future studies in routine clinical 
settings in primary care.
Our approach has other limitations. Co-occurrence of 
symptoms in the same person might provide further 
important information on risk of Parkinson’s disease; 
however, our analysis included only ﬁ rst presentation of 
each symptom in isolation, irrespective of other already 
existing symptoms, and does not allow conclusions 
regarding the predictive value of combinations of 
symptoms for Parkinson’s disease within one person. 
Assessment of risk associated with co-occurring 
symptoms is an important area for future study.
Patients and controls were overall well matched, 
although the patients had lower social deprivation. Thus, 
a bias due to lower social deprivation cannot be excluded. 
However, the absence of a diﬀ erence between groups in 
neck pain or stiﬀ ness argues against this. Also, such a 
bias would not explain the increase in incidence of 
symptoms in the years approaching diagnosis of 
Parkinson’s disease.
A further limitation of the study is that the diagnosis of 
Parkinson’s disease in primary care is likely to be delayed. 
This is a limitation particularly for the 2 year timepoint, 
when many patients are likely to already have had mild 
parkinsonism. Conversely, occurrence of symptoms 
associated with reduced survival might have been 
underestimated, especially for the 10 year timepoint. This 
underestimation might apply particularly to the autonomic 
features that were identiﬁ ed in the shorter time periods 
before diagnosis. Furthermore, the decreasing number of 
patients with longer follow-up precluded examination of 
ﬁ rst occurrence more than 10 years before diagnosis. 
Thus, presentations at an even earlier stage were probably 
Panel: Research in context
Systematic review
We searched Medline up to Sept 4, 2014, for reports in English with the terms 
“Parkinson’s disease” and “case-control” and “prodromal” or “prediagnostic” or 
“pre-diagnostic”, yielding 42 reports. We repeated the search replacing “case-control” 
with “cohort”, yielding 33 articles. We screened these reports for content and identiﬁ ed 
only one paper24 that addressed a wide range of prediagnostic symptoms of Parkinson’s 
diseases in a case-control or cohort study design.
Interpretation
In this large study of a representative primary care population, we show for the ﬁ rst time 
the increased incidence of a wide range of motor and non-motor presentations within 
10 years before diagnosis of Parkinson’s disease. These manifestations of Parkinson’s 
disease can be troubling enough to lead to clinical presentation in routine primary care 
consultations before a clinical diagnosis, and provide insight into the pathophysiological 
process in the earliest stages of Parkinson’s disease.
Articles
64 www.thelancet.com/neurology   Vol 14   January 2015
missed and the ﬁ rst onset of some of the prediagnostic 
features occurs probably even earlier.
Finally, the diagnosis of Parkinson’s disease might not 
have been conﬁ rmed by specialist input in all cases and a 
few patients probably had an atypical parkinsonian 
syndrome, which might have become apparent during 
later follow-up.39 Also, the data are not representative for 
young-onset Parkinson’s disease because patients under 
age 50 years were excluded, but this population 
represents only a small proportion of individuals with 
Parkinson’s disease.
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